PATIENT BLOOD MANAGEMENT / BLOOD CONSERVATION

Aryeh Shander, MD, FCCM, FCCP

Chief, Department of Anesthesiology, Critical Care and Hyperbaric Medicine.
Englewood Hospital and Medical Center, Englewood, New Jersey

Clinical Professor of Anesthesiology, Medicine and Surgery
Mount Sinai School of Medicine, New York
Disclosure

Speakers bureau: Baxter, Zymogenetics, Novartis, CSL, Covidien and Masimo

Grants: Centocor OBI, Zymogenetics, Novartis and Masimo

Consultant: Baxter, Centocor OBI, Novartis, J&J, CSL, AMAG and Vifor
“…the sweeping story of a substance that has been feared, revered, mythologized, and used in magic and medicine from earliest times — a substance that has become the center of a huge, secretive, and often dangerous worldwide commerce.”

—From the publisher’s description of the book

Issues with blood
Anemia
Transfusion
Patient outcome
What to do about it
USDHSS: In 2006, total of 14,650,000 units of RBC/WB transfused in the U.S.
- 3.3% increase from 2004
- ~20% in cardiac surgery

AHRQ: in 2007, blood transfusions occurred in 1/10 of all hospital stays that had a procedure
- A cumulative growth of 140% from 1997
- One of the fastest growing top-five procedures
# SUPPLY - BLOOD CENTERS

<table>
<thead>
<tr>
<th><strong>American Red Cross (ARC)</strong>&lt;sup&gt;1,2&lt;/sup&gt;</th>
<th><strong>American Blood Centers (ABC)</strong>&lt;sup&gt;3,4&lt;/sup&gt;</th>
<th><strong>Blood Systems</strong>&lt;sup&gt;5&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Responsible for ~45% of US blood supply</td>
<td>- Conglomerate of smaller blood centers in US and Canada</td>
<td>- Represent ~9% of ABC’s US share of blood supply&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>- Largest single supplier of US blood supply</td>
<td>- 685 donor centers in 45 states</td>
<td>- Testing divided into laboratories in Arizona and Texas</td>
</tr>
<tr>
<td>- Leader in research and testing</td>
<td>- Responsible for ~55% of US blood supply</td>
<td>- Developed UBS</td>
</tr>
<tr>
<td>- Implemented the first nationwide hemo- vigilance program</td>
<td>- Members represent 77 community-based blood donor centers</td>
<td></td>
</tr>
<tr>
<td>- Protocol development and safer transfusions</td>
<td>- Provide blood products to more than 3500 health care facilities and hospitals</td>
<td></td>
</tr>
</tbody>
</table>
The 70-to-80-year-olds have an eightfold higher RBC consumption than 20-to-40-year-olds.
Predicted RBC Collections and Transfusions

Proportion of Population

- <16 years old
- 16 to 64 years old
- 65 years and over
- Units Collected (Projected)
- Units Transfused (Projected)

ARC 2011
A CLINICIAN’S PERCEPTIONS

- Safety of BLOOD - high
- Risk of BLOOD - low
- Risk of Anemia - unknown
- Risk of Surgical Bleeding – low
- Transfusions- rare
TRANSFUSION of Allogeneic Blood

- Past: Considered a therapeutic intervention
- Present/future: A negative outcome

WHY?
TRANSFUSION of Allogeneic Blood

- Transfusion outcome
- Transfusion risks
- Transfusion variability
- Modifiable risk (for transfusion) ignored
- We cannot continue on this journey

Sphan et.al. Anesthesiology 2010
Shander et.al. JAMA 2011
Risks and Benefit “Equation”

- Variability in transfusion of ALL components
- Immediate risks – FDA and blood providers obsession – ZERO RISK
- Unknown benefit – close to 120 years in the dark
Efficacy Of Red Blood Cell Transfusion In The Critically Ill: A Systemic Review Of the Literature

- N = 45 articles reviewed
- Outcome measures: Mortality, Infections, MODS, ARDS
- 42 of the 45 studies showed the risks of RBC transfusion outweighed the benefits
- In adult, ICU, trauma, and surgical patients, RBC transfusions are associated with increased morbidity and mortality

Marik PE.et.al. Crit Care Med. 2008;36(9):2667-74
Association between blood transfusion and the risk of death (odds ratio [OR] and 95% confidence interval [CI]). ACS, abdominal compartment syndrome; ICU, intensive care unit
Association between blood transfusion and the risk of infectious complications (odds ratio [OR] and 95% confidence interval [CI]).

ICU, intensive care unit

Association between blood transfusion and the risk of developing adult respiratory distress syndrome (odds ratio [OR] and 95% confidence interval [CI]). ICU, intensive care unit

Marik PE.et.al. Crit Care Med. 2008;36(9):2667-74
The 1-3 units of RBC transfused
Side Effects And Hazards For RBC Transfusion

- Acute and delayed hemolytic transfusion reactions
- Transfusion-related acute lung injury (TRALI)
- Administrative errors
- Bacterial contamination
- Storage lesions
- Viral transmission (eg, CMV, HIV, HBV, HCV)
- Alloimmunization
- Volume overload
- Iron overload
The Coming Plague?

“It is sobering to consider that if a new agent with a long silent carrier state and efficient blood transmission (HIV prototype) were to appear, the blood component collectors would be scarcely better prepared to interdict a transfusion transmitted epidemic than they were during the early days of AIDS in 1977."

Klein H. Emerging Infectious Disease and Blood Transfusion TATM 2005;7(1):18

U.S. Department of Health and Human Services
National Institutes of Health
Transfusion Medicine In American Undergraduate Medical Education

- Transfusion is the most common procedure in hospitals
- N = 86 American medical schools surveyed (AAMC)
- 83% administrators reported - didactic lectures
- 48% of medical schools providing 1 or 2 hours of lectures
- Handful reported small group sessions on transfusion medicine (6%)
- 92% administrators were unfamiliar with the 1989 or the 1995 TMAA curricula.

Karp JK. et al. Transfusion. 2011 Nov;51(11):2470-9
Transfusion Practice

Influence of knowledge and attitudes on the quality of physicians' transfusion practice

- Amount of transfused products was inversely proportional to physician knowledge of transfusion medicine
- Attending MD - lower scores, greater confidence than residents
- >60% of residents inappropriate transfusion due attending pressure (once a month)
Variability of Transfusion Rates For Matched Patients

Transfusion 2007

TKR – Txn Rate (n=1,401)
Variation In Use Of Blood Transfusion In CABG Surgery

- To assess variation in use of allogeneic red blood cell (RBC), FFP, and platelet transfusions in patients undergoing (CABG) surgery.
- N = 102,470 CABG patients in 2008 at 798 sites in the US (STS Adult Cardiac Surgery Database)
- The rates of transfusions ranged from:
  - 7.8% to 92.8% for RBCs
  - 0% to 97.5% for fresh-frozen plasma
  - 0.4% to 90.4% for platelets.
- Multivariable analysis transfusion rates varied by:
  - Geographic location (P=.007), Academic status (P=.03), and Hospital volume (P<.001)
- Wide variability in rates of transfusion of all blood products in CABG operations in US hospitals

Benette-Guerrero et. al., JAMA. 2010; 13;304(14):1568-75.
Variation in use of blood transfusion in CABG surgery

Bennett-Guerrero E et al. JAMA 2010
WHO Definition of Anemia and Hgb. Distribution in General population

Anemia in Men: Hb < 13 g/dL

Anemia in Women: Hb < 12 g/dL

Hb distribution in women: 13.3 ± 0.9 g/dL

Hb distribution in men: 15.2 ± 0.9 g/dL

N = 40,000 (NHANES III, 1988-1994)

Anemia Is Often “Accepted” As A Normal Part Of Doing Business

- We have a long tradition of accepting anemia as a relatively harmless problem that can be corrected easily with transfusion.
- For the medical community transfusion as treatment for anemia remains a default position.
- New paradigm - Anemia is an independent risk of morbidity and mortality regardless of the level of hemoglobin.
Anemia: A Potent Multiplier of Mortality

N = 1.1 million (5% Medicare sample, 1996-1997)

N= 17,676 patients with AMI from 57 US hospitals - AMI database (Jan 2000 - Dec 2008).

Moderate to severe HAA developed in 3,551 patients (20%).

The mean (SD) phlebotomy volume was higher:
• HAA (173.8 [139.3] mL) vs those without HAA (83.5 [52.0 mL]; P < .001)

There was significant variation in the mean diagnostic blood loss across hospitals
• For every 50 mL of blood drawn, the risk of moderate to severe HAA increased by 18% (relative risk [RR], 1.18; 95% confidence interval [CI], 1.13-1.22)

Blood loss from phlebotomy is independently associated with the development of HAA.

Variation in mean diagnostic blood loss (DBL) across the 57 hospitals

Does Preoperative Anemia Adversely Affect Colon and Rectal Surgery Outcomes?

- 2005-2008 - NSQIP (251 hospitals)
- CO – MI, CVA, AKI, Mortality and HLOS
- N – 23,348 – 47.4 % Anemic
- Uni, multi, logistic regression and propensity scoring

<table>
<thead>
<tr>
<th>Anemia</th>
<th>HCT</th>
<th>N</th>
<th>CO - OR</th>
<th>HLOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>(&gt;38%)</td>
<td>12,281</td>
<td>1.0</td>
<td>-</td>
</tr>
<tr>
<td>Mild</td>
<td>(30-37%)</td>
<td>9037</td>
<td>1.47</td>
<td>-</td>
</tr>
<tr>
<td>Moderate</td>
<td>(26-29%)</td>
<td>1726</td>
<td>1.87</td>
<td>1.2</td>
</tr>
<tr>
<td>Severe</td>
<td>(21-25%)</td>
<td>304</td>
<td>2.1</td>
<td>1.6</td>
</tr>
</tbody>
</table>

Preoperative Anemia Is Associated With Postoperative Mortality

Hb<12 g/dL for women and <13 g/dL for men

Preoperative anemia
No anemia

Association between Intra-operative Blood Transfusion and Mortality and Morbidity in Patients Undergoing Non-Cardiac Surgery

- N = 10,100 patients (general, vascular, or orthopedic surgery)
- Intraoperative blood transfusion associated with an increased risk of death (odds ratio [OR], 1.29; 95% CI, 1.03–1.62)
- Patients receiving one or two units of erythrocytes more likely to have:
  - Pulmonary complications (OR, 1.76; 95% CI, 1.48–2.09)
  - Sepsis (OR, 1.43; 95% CI, 1.21–1.68)
  - Thromboembolic complications (OR, 1.77; 95% CI, 1.32–2.38)
  - Wound complications (OR, 1.87; 95% CI, 1.47–2.37)
- Intraoperative blood transfusion is associated with a higher risk of mortality and morbidity in surgical patients with severe anemia

### Impact of Intraoperative Transfusion on 30-Day Mortality and 30-Day Complications

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Transfusion Group, Outcome Rate (%)</th>
<th>No Transfusion Group, Outcome Rate (%)</th>
<th>Adj OR Txf vs. No Txf (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>6.44</td>
<td>4.26</td>
<td>1.29 (1.03, 1.62)</td>
</tr>
<tr>
<td>Cardiac complications</td>
<td>2.08</td>
<td>1.40</td>
<td>1.40 (0.97, 2.03)</td>
</tr>
<tr>
<td>Pulmonary complications</td>
<td>12.6</td>
<td>6.03</td>
<td>1.76 (1.48, 2.09)</td>
</tr>
<tr>
<td>Renal complications</td>
<td>2.69</td>
<td>1.85</td>
<td>1.32 (0.93, 1.88)</td>
</tr>
<tr>
<td>CNS complications</td>
<td>0.69</td>
<td>0.58</td>
<td>0.84 (0.43, 1.64)</td>
</tr>
<tr>
<td>Sepsis complications</td>
<td>16.4</td>
<td>9.81</td>
<td>1.43 (1.21, 1.68)</td>
</tr>
<tr>
<td>Wound complications</td>
<td>9.17</td>
<td>4.65</td>
<td>1.87 (1.47, 2.37)</td>
</tr>
<tr>
<td>Thrombo-embolic Complications</td>
<td>4.07</td>
<td>1.89</td>
<td>1.77 (1.32, 2.38)</td>
</tr>
</tbody>
</table>

Risk ratios (95% CI) compared with patients receiving no blood products by timing of administration

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intraoperative</th>
<th>Within 48 h postop</th>
<th>After 48 h postop</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital mortality</td>
<td>7.71 (4.44–13.38)</td>
<td>7.09 (3.95–12.72)</td>
<td>10.37 (5.21–20.63)</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>3.98 (2.77–5.74)</td>
<td>4.12 (2.82–6.03)</td>
<td>10.78 (7.03–16.52)</td>
</tr>
<tr>
<td>Sepsis/DSWI</td>
<td>3.74 (1.85–7.57)</td>
<td>4.11 (1.99–8.48)</td>
<td>11.84 (5.56–25.23)</td>
</tr>
</tbody>
</table>

Riddell RE et al. *Can J Cardiol* 2009; 25 (suppl B):122b
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery

FOCUS Trial

- 2016 subjects from 42 Hosp 60% US
- Patients with Hip Fx > 50 y/o ~ 82 y/o
- Randomized to Hb 10 (L) or 8(R) with symptoms
- 1° - Death or walk across the room in 60 days
- # 1 reason for Tx in R – Tachycardia and Hypotension
- Results show no difference in outcome

1. Liberal group received 65% more transfusion

Kaplan-Meier plots showing the crude cumulative incidence of 6-month mortality among patients who did and those who did not receive red blood cell (RBC) transfusion.

Prospective database
N=2,358
with AMI
8.1% of patients received transfusion


Impact of Red Blood Cell Transfusion on Clinical Outcomes in Patients with Acute Myocardial Infarction

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes

Sunil V. Rao1*, John A. Eikelboom2, Christopher B. Granger1, Robert A. Harrington1, Robert M. Califf3, and Jean-Pierre Bassand4

Impact of Blood Transfusion on Short- and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction

Mehdi H. Shishehbor, Surabhi Madhwal, Vivek Rajagopal, Amy Hsu, Peter Kelly, Hitinder S. Gurm, Samir R. Kapadia, Michael S. Lauer, and Eric J. Topol

J. Am. Coll. Cardiol. Intv. 2009;2;46-53
For asymptomatic patients, it would seem prudent to avoid the use of arbitrary cutoffs (such as a hemoglobin "8 g/dl) to trigger transfusion. With minimal potential gain to offset any adverse effects, transfusion could in theory be more likely to cause harm in these circumstances.
ICCTO — International Consensus Conference on Transfusion Outcomes

• > 30,000 citations – 494 analysed – 450 clinical scenarios

• Appropriateness of ABT based on improving **health** outcomes

ALL transfused patients had Hb < 7.9 g/dL
No one appropriate if Hb ≥ 8.0 g/dL

ABT, allogeneic blood transfusions; Hb, haemoglobin
### WHY IT MATTERS?

Mean Hospital Amount ($) Paid per Selected Component Unit in 2006 - 2008

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Red cells, leukocyte filtered</td>
<td>223.09*</td>
<td>211.50</td>
<td>5.5*</td>
</tr>
<tr>
<td>Fresh Frozen Plasma</td>
<td>57.78</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Plasma Frozen Within 24 Hours After Phlebotomy</td>
<td>53.85*</td>
<td>52.63</td>
<td>2.3*</td>
</tr>
<tr>
<td>Whole-blood-derived platelets, not leukocyte reduced or irradiated</td>
<td>64.98</td>
<td>65.54</td>
<td>-0.9</td>
</tr>
<tr>
<td>Apheresis platelets, leukocyte reduced</td>
<td>538.56*</td>
<td>525.05</td>
<td>2.6*</td>
</tr>
<tr>
<td>Cryoprecipitate</td>
<td>65.10*</td>
<td>46.67</td>
<td>39.5*</td>
</tr>
</tbody>
</table>

*Significantly different from 2006 data.

---

2009 National Blood collection and utilization survey report
Activity Based Cost of Transfusion

Mean RBC product cost
Mean cost per RBC txn
Mean txn cost per surgical pt txed
Outcome of Patients Who Refuse Transfusion After Cardiac Surgery

- N= 322 Witnesses and 87,453 non-Witnesses cardiac surgery patients
- Non-Witnesses, 38,467 did not receive blood transfusions and 48,986 did
- Witnesses had fewer acute complications and shorter length of stay than matched transfused patients:
  - myocardial infarction, 0.31% vs 2.8% (P = .01);
  - hospital length of stay (15th, 50th, and 85th percentiles), 5, 7, and 11 vs 6, 8, and 16 days (P <.001)
  - Witnesses had better 1-year survival (95%; 95% CI, 93%-96%; vs 89%; 95% CI, 87%-90%; P = .007)
  - Similar 20-year survival (34%; 95% CI, 31%-38%; vs 32% 95% CI, 28%-35%; P = .90)
- Blood management strategies do not appear to place patients at heightened risk for reduced long-term survival

Mirrored histogram of propensity scores

Survival of matched patients. Error bars indicate Kaplan-Meier estimates at 5, 10, 15, and 20 years after surgery.
Is fresh frozen plasma clinically effective? An update of a systematic review of randomised controlled trials

- Primary outcome - effect of FFP on survival
- Trials reviewed up to July 2011 (n = 21)
- Trials identified from searches of:
  - MEDLINE, EMBASE, CINAHL, The Cochrane Library, and the UKBTS/SRI Transfusion Evidence Library
- Prophylactic and therapeutic FFP use in:
  - liver disease, cardiac surgery, warfarin anticoagulation reversal, TTP treatment, plasmapheresis
- Results: no significant benefit for FFP use across all the clinical conditions

Yang L et al. Transfusion 2012
“New” strategies for the optimal use of platelet transfusions

- Severe thrombocytopenia is presumed to be high risk for bleeding
- Controversy as to the optimal use of platelets (amount and timing)
- Lack of data on different regimens and clinical outcomes
- Platelet Tx strategy - needs to be addressed in clinical trials: examples of such trials:
  - *The PLADO study* (Prophylactic PLAtelet Dose)
  - *The SToP study* (Strategies for the Transfusion of Platelets)

Established Transfusion Risks/Complications – immediate (FDA)

- Acute and delayed hemolytic transfusion reactions
- Transfusion-related acute lung injury (TRALI)
- Administrative errors
- Bacterial contamination
- Storage lesions
- Viral transmission (eg, CMV, HIV, HBV, HCV)
- Alloimmunization
- Volume overload
- Iron overload

1 Unit RBC
PERFUSION
Microvascular Dysfunction as a Cause of Organ Dysfunction

Vincent JL et al. Critical Care 2005; 9 Sup 4:s9-s12
HEMORRHAGIC SHOCK

Functional capillary density predicts survivors vs. non-survivors

### Survival of donor WBC in severe trauma patients

**Quantitative allele-specific PCR**

<table>
<thead>
<tr>
<th>Sample collection day</th>
<th>Standard curve</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC subset</td>
<td></td>
</tr>
<tr>
<td>Pre-Tx</td>
<td></td>
</tr>
<tr>
<td>Post-Tx</td>
<td></td>
</tr>
<tr>
<td>1D</td>
<td>10^3</td>
</tr>
<tr>
<td>2D</td>
<td>10^2</td>
</tr>
<tr>
<td>3D</td>
<td>10^1</td>
</tr>
<tr>
<td>2W</td>
<td>10^0</td>
</tr>
<tr>
<td>6M</td>
<td></td>
</tr>
<tr>
<td>1Y</td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**

- CD4^+:
- CD8^+:
- CD15^+:
- CD19^+:
BLOOD TRANSFUSIONS AND THE SUBSEQUENT RISKS – of Hematologic malignancies (HM)

Chang et al. Transfusion 2010; 50: 2249-2257

US Case-control study conducted by NCI
- 77,488 elderly HM cases and 154,509 controls
- History of transfusion in 7.9% of HM cases vs. 5.9% of controls

Patterns of elevated risk for lymphoplasmacytic and marginal zone lymphomas suggest an etiologic role for transfusion

LPL – Lymphoplasmacytic lymphoma
MZL – Marginal zone lymphoma
Nosocomial Infections in the ICU


N=2,085

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Transfused</th>
<th>Nontransfused</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Patients with NI</td>
<td>7.5</td>
<td>14.3</td>
<td>5.8</td>
</tr>
</tbody>
</table>
Current Solutions

- Education
- Blood Management
- Patient Blood Management – SABM – we have results (see NHA)
- Regulation
- Payment
Guideline to provide recommendations about Hgb concentration thresholds and other clinical variables that “trigger” RBC transfusions

Systematic review of the literature only RCT (1950 – Feb, 2011)

Examine proportion of patients who received any RBC transfusion and the number of RBC units transfused to describe the effect of restrictive transfusion strategies on RBC use

To determine the clinical consequences of restrictive transfusion strategies, we examined:

- overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay

Recommendations

- **Recommendation 1:** adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients
  - (Grade: strong recommendation; high-quality evidence)

- **Recommendation 2:** adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less
  - (Grade: weak recommendation; moderate-quality evidence)

- **Recommendation 3:** cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome
  - (Grade: uncertain recommendation; very low-quality evidence)

- **Recommendation 4:** suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration
  - (Grade: weak recommendation; low-quality evidence).

Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices

- 1402 surveys from 1061 institutions - United States (677 institutions) and Canada (34 institutions) [32% response rate]
- 78% of anesthesiologists and 67% of perfusionists reporting having read all, part, or a summary of the Guidelines.
- 26% of respondents reported 1 or more practice changes in response to the Guidelines
- Only 4 of 38 Guideline recommendations were reported by >5% of respondents to have been changed in response to the Guidelines
- Little change in clinical practices was attributed to the STS/SCA Guidelines

Blood Management

Patient Blood Management

Donor Blood Management

Transfusion
Patient blood management

“Is the timely application of evidence based medical and surgical concepts designed to manage anaemia, optimise haemostasis, and minimise blood loss and blood transfusion in order to improve patient outcomes.”

A multimodality approach
SABM – Administrative And Clinical Standards
For Patient Blood Management Programs
94% of transfusions in surgical patients can be attributed to:
- low preoperative hemoglobin levels, excessive surgical blood loss, and/or inappropriate transfusion practices

PBM relies on 3 pillars:
- (1) optimizing hematopoiesis
- (2) minimizing bleeding and blood loss
- (3) harnessing and optimizing physiological tolerance of anemia

The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?

PBM strategies used:
- Pre-op hemoglobin optimization
- Intra-op ANH
- Autologous transfusion (cell salvage)
- Meticulous surgical technique
- Endovascular vein harvesting
- Point-of-care coagulation testing
- Targeted pharmacotherapy
- Tolerance of peri-operative anemia (60–70 g/L depending on patient-specific physiology)

Algorithm For The Detection, Evaluation, And Management Of Preoperative Anemia


Hb < 120 g/l for females
Hb < 130 g/l for males

Evaluation necessary

Iron status?

Ferritin < 30 µg/l and/or TSAT < 15-20%

Iron deficiency
Referral to gastroenterologist to rule out malignancy

Rule out iron deficiency
Inflammation/chronic disease

Ferritin 30-100 µg/l and/or TSAT > 20%

Ferritin > 100 µg/l and/or TSAT > 20%

Serum creatinine
Glomerular filtration rate

Low

Chronic kidney Disease (CKD)
Referral to nephrologist

Normal

Vitamin B12 and/or folic acid
Normal
Low

Iron therapy
1) Oral iron in divided doses
2) IV iron if cannot tolerate oral iron, GI uptake problems (Hepcidin), or short timeline

Ferritin < 30 µg/l and/or TSAT < 15-20%

Iron deficiency
Referral to gastroenterologist to rule out malignancy

Rule out iron deficiency
Inflammation/chronic disease

Ferritin 30-100 µg/l and/or TSAT > 20%

Ferritin > 100 µg/l and/or TSAT > 20%

Serum creatinine
Glomerular filtration rate

Low

Chronic kidney Disease (CKD)
Referral to nephrologist

Normal

Vitamin B12 and/or folic acid
Normal
Low

Iron therapy
1) Oral iron in divided doses
2) IV iron if cannot tolerate oral iron, GI uptake problems (Hepcidin), or short timeline

No Response

Erythropoiesis-stimulating agent therapy
Folic acid and/or vitamin B12 therapy
CABG outcomes
PBMP vs non-PBMP

PBMP cohort (n=586)
Non-PBMP cohort (n=586)

- % Transfused: 10.6% vs 42.5%
- Mortality: 0.8% vs 2.5%
- Serious complication: 11.1% vs 18.7%

N=586

CABG, coronary artery bypass graft; PBMP, patient blood management programme
Bearing in mind that patient blood management means that before surgery every reasonable measure should be taken to Optimize the patient’s own blood volume, to minimize the patient’s Blood loss and to harness and optimize the patient-specific physiological Tolerance of anemia following the WHO’s guide for optimal clinical use (three pillars of Patient Blood Management)

DHHS Selected Recommendation on PBM:
- Wide variability in transfusion indicated both excessive and inappropriate use of blood transfusion in the U.S.
- PBM programs have shown a significant reduction in blood use without an increase in patient harm
Consequences of overuse: tests, treatments and procedures

Overuse may be defined as:

“The use of a health service in circumstances where the likelihood of benefit is negligible and, therefore, the patient faces only the risk of harm.”

The focus is to identify and eliminate overuse

NPSG provides for incremental implementation and an evaluation of the effectiveness

http://www.jointcommission.org/assets/1/6/HAP_NPSG_Overuse_Rpt_2011-11-14
SUMMARY

- Transfusion not a science
- No demonstration of benefit = all risk!
- Directed therapy – RBC, FFP, Platelets and fluid
- Guidelines – From Hgb. alone to symptoms
- Reduce or eliminate “overuse”
- Emerging data support that:
  - PBM is safe and effective in providing better care and improving patients’ outcomes while reducing transfusion of allogeneic blood components
Despite the cost of living, it is still very popular and even when appropriate, transfusion is preventable.

Thank you.